Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

X
Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Cibisatamab (Primary) ; Ciforadenant (Primary) ; Cobimetinib (Primary) ; Docetaxel (Primary) ; Evolocumab (Primary) ; Gemcitabine (Primary) ; Ipatasertib (Primary) ; Linagliptin (Primary) ; Pemetrexed (Primary) ; Sacituzumab govitecan (Primary) ; Tocilizumab
  • Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms MORPHEUS; Morpheus Lung; MORPHEUS-NSCLC
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 31 May 2024 Planned End Date changed from 30 Sep 2027 to 30 Nov 2026.
    • 31 May 2024 Planned primary completion date changed from 30 Jun 2026 to 30 Sep 2025.
    • 31 May 2024 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top